Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 4 full-time employees. The company went IPO on 2020-09-25. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. The company has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.
Follow-Up Questions
Greenwich Lifesciences Inc의 CEO는 누구입니까?
Mr. Snehal Patel은 2010부터 회사에 합류한 Greenwich Lifesciences Inc의 Chief Executive Officer입니다.
GLSI 주식의 가격 성능은 어떻습니까?
GLSI의 현재 가격은 $9.28이며, 전 거래일에 increased 0.03% 하였습니다.
Greenwich Lifesciences Inc의 주요 사업 주제나 업종은 무엇입니까?
Greenwich Lifesciences Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Greenwich Lifesciences Inc의 시가총액은 얼마입니까?
Greenwich Lifesciences Inc의 현재 시가총액은 $126.5M입니다
Greenwich Lifesciences Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 4명의 분석가가 Greenwich Lifesciences Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 5명의 매수, 1명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
